It’s a short newsletter today because my attention will be on Washington today. I plan to watch as much of the Senate hearing as I can stand. There’s a lot
I often act all exasperated when data emerges that shows that the net prices of medicines are going down, feigning frustration at the fact that there has been limited recognition
So to strip things down to the basics, most cost-effectiveness analyses of drugs look at only three components: 1) What does it cost? 2) How does it extend or improve